Naturally this is a time for a resurgence of blathering about how Journal Impact Factors are a hugely flawed measure of the quality of individual papers or scientists. Also it is a time of much bragging about recent gains....I was alerted to the fact that they were out via a society I follow on Twitter bragging about their latest number.
2012 NPP impact Factor is 8.678! 6 of 135 titles in Psychiatry 8 of 260 titles in Pharmacology & Pharmacy 16 of 251 titles in Neurosciences
— ACNP (@ACNPorg) June 19, 2013
Of course, one must evaluate such claims in context. Seemingly the JIF trend is for unrelenting gains year over year. Which makes sense, of course, if science continues to expand. More science, more papers and therefore more citations seems to me to be the underlying reality. So the only thing that matters is how much a given journal has changed relative to other peer journals, right? A numerical gain, sometimes ridiculously tiny, is hardly the stuff of great pride.
So I thought I'd take a look at some journals that publish drug-abuse type science. There are a ton more in the ~2.5-4.5 range but I picked out the ones that seemed to actually have changed at some point.
Neuropsychopharmacology, the journal of the ACNP and subject of the abovequoted Twitt, has closed the gap on arch-rival Biological Psychiatry in the past two years, although each of them trended upward in the past year. For NPP, putting the sadly declining Journal of Neuroscience (the Society for Neuroscience's journal) firmly behind them has to be considered a gain. J Neuro is more general in topic and, as PhysioProf is fond of pointing out does not publish review articles, so this is expected. NPP invented a once-annual review journal a few years ago and it counts in their JIF so I'm going to score the last couple of years' of gain to this, personally.
Addiction Biology is another curious case. It is worth special note for both the large gains in JIF and the fact it sits atop the ISI Journal Citation Reports (JCR) category for Substance Abuse. The first jump in IF was associated with a change in publisher so perhaps it started getting promoted more heavily and/or guided for JIF gains more heavily. There was a change in editor in there somewhere as well which may have contributed. The most recent gains, I wager, have a little something to do with the self-reinforcing virtuous cycle of having topped the category listing in the ISI JCR and having crept to the top of a large heap of ~2.5-4.5 JIF behavioral pharmacology / neuroscience type journals. This journal had been quarterly up until about two years ago when it started publishing bimonthly and their pre-print queue is ENORMOUS. I saw some articles published in a print issue this year that had appeared online two years before. TWO YEARS! That's a lot of time to accumulate citations before the official JIF window even starts counting. There was news of a record number of journals being excluded from the JCR for self-citation type gaming of the index....I do wonder why the pre-print queue length is not of concern to ISI.
PLoS ONE is an interest of mine, as you know. Phil Davis has an interesting analysis up at Scholarly Kitchen which discusses the tremendous acceleration in papers published per year in PLoS ONE and argues a decline in JIF is inevitable. I tend to agree.
Neuropharmacology and British Journal of Pharmacology are examples of journals which are near the top of the aforementioned mass of journals that publish normal scientific work in my fields of interest. Workmanlike? I suppose the non-perjorative use of that term would be accurate. These two journals bubbled up slightly in the past five years but seem to be enjoying different fates in 2012. It will be interesting to see if these are just wobbles or if the journals can sustain the trends. If real, it may show how easily one journal can suffer a PLoS ONE type of fate whereby slightly elevated JIF draws more papers of a lesser eventual impact. While BJP may be showing the sort of virtuous cycle that I suspect Addiction Biology has been enjoying. One slightly discordant note for this interpretation is that Neuropharmacology has managed to get the online-to-print publication lag down to some of the lowest amongst its competition. This is a plus for authors who need to pad their calendar-year citation numbers but it may be a drag on the JIF since articles don't enjoy as much time to acquire citations.